| This week's Fierce Biotech is brought to you by IQVIA. |
| Solutions for you to drive healthcare forward™ |
 |
 |
Mitigating Trial Risk in ALS Clinical DevelopmentKey strategies for overcoming common hurdles in ALS researchThe development of new treatments has been slow, with only two approved disease-modifying drugs that offer limited benefit. But significant advances in immuno-neurology have set the stage for promising novel treatments that could offer hope to these families and change the course of this disease.IQVIA has been at the leading edge of this research. Our experts have identified key strategies for overcoming common hurdles and strengthening patient centricity in ALS research, and for driving new progress that can benefit ALS patients across the globe. |
.png) |
| 4820 Emperor Boulevard, Durham, NC 27703, USA |
| Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about IQVIA and our services. Such information also may be transferred to IQVIA companies in other countries. © 2022. All rights reserved. IQVIA is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. |
| If you no longer wish to receive communications from IQVIA, please opt out here. Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Questex, LLC |
